WBP2 and breast carcinoma: Our findings provide a novel insight into how ERα signalling regulates the response of ERα-positive breast tumours to chemotherapy, and to the best of our knowledge, is the first evidence of WBP2-mediated drug resistance in ERα-positive breast cancer cells.